A detailed history of Amalgamated Bank transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Amalgamated Bank holds 2,154 shares of BPMC stock, worth $197,349. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,154
Previous 2,154 -0.0%
Holding current value
$197,349
Previous $232,000 14.22%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$85.18 - $108.78 $9,284 - $11,857
109 Added 5.33%
2,154 $232,000
Q1 2024

Apr 23, 2024

SELL
$73.17 - $99.79 $489,946 - $668,193
-6,696 Reduced 76.6%
2,045 $194,000
Q4 2023

Feb 06, 2024

SELL
$43.96 - $92.84 $26,727 - $56,446
-608 Reduced 6.5%
8,741 $806,000
Q3 2023

Nov 08, 2023

BUY
$46.9 - $66.0 $6,425 - $9,042
137 Added 1.49%
9,349 $470,000
Q2 2023

Aug 11, 2023

BUY
$42.2 - $66.37 $31,312 - $49,246
742 Added 8.76%
9,212 $582,000
Q1 2023

May 02, 2023

SELL
$37.97 - $50.0 $49,740 - $65,500
-1,310 Reduced 13.39%
8,470 $381,000
Q4 2022

Feb 10, 2023

BUY
$41.06 - $66.48 $6,651 - $10,769
162 Added 1.68%
9,780 $428,000
Q3 2022

Nov 09, 2022

BUY
$49.93 - $77.7 $7,589 - $11,810
152 Added 1.61%
9,618 $634,000
Q2 2022

Aug 15, 2022

BUY
$45.23 - $70.15 $2,306 - $3,577
51 Added 0.54%
9,466 $478,000
Q1 2022

Jun 30, 2022

SELL
$54.1 - $110.08 $38,248 - $77,826
-707 Reduced 6.98%
9,415 $601,000
Q4 2021

Feb 15, 2022

SELL
$94.25 - $115.99 $10,273 - $12,642
-109 Reduced 1.07%
10,122 $1.08 Million
Q3 2021

Oct 29, 2021

SELL
$80.98 - $109.47 $51,503 - $69,622
-636 Reduced 5.85%
10,231 $1.05 Million
Q2 2021

Aug 16, 2021

BUY
$82.78 - $101.0 $247,263 - $301,687
2,987 Added 37.91%
10,867 $956,000
Q1 2021

May 13, 2021

SELL
$90.71 - $108.28 $69,755 - $83,267
-769 Reduced 8.89%
7,880 $766,000
Q4 2020

Feb 12, 2021

BUY
$92.08 - $124.48 $4,143 - $5,601
45 Added 0.52%
8,649 $969,000
Q3 2020

Oct 30, 2020

SELL
$66.45 - $92.7 $5,183 - $7,230
-78 Reduced 0.9%
8,604 $798,000
Q2 2020

Aug 10, 2020

SELL
$57.09 - $79.27 $31,627 - $43,915
-554 Reduced 6.0%
8,682 $677,000
Q1 2020

May 13, 2020

BUY
$48.11 - $82.22 $7,841 - $13,401
163 Added 1.8%
9,236 $540,000
Q4 2019

Feb 13, 2020

BUY
$66.73 - $82.59 $28,894 - $35,761
433 Added 5.01%
9,073 $727,000
Q3 2019

Nov 13, 2019

SELL
$72.9 - $101.41 $8,820 - $12,270
-121 Reduced 1.38%
8,640 $635,000
Q2 2019

Aug 14, 2019

BUY
$73.54 - $97.8 $183,850 - $244,500
2,500 Added 39.93%
8,761 $826,000
Q1 2019

May 15, 2019

BUY
$48.7 - $86.6 $9,788 - $17,406
201 Added 3.32%
6,261 $501,000
Q4 2018

Feb 15, 2019

BUY
$45.57 - $74.26 $276,154 - $450,015
6,060 New
6,060 $327,000
Q3 2018

Nov 14, 2018

SELL
$58.91 - $78.32 $372,370 - $495,060
-6,321 Closed
0 $0
Q2 2018

Jul 18, 2018

BUY
$60.96 - $101.18 $38,892 - $64,552
638 Added 11.23%
6,321 $401,000
Q1 2018

May 22, 2018

SELL
$73.28 - $102.95 $6,888 - $9,677
-94 Reduced 1.63%
5,683 $521,000
Q4 2017

Feb 13, 2018

BUY
$62.91 - $88.32 $52,655 - $73,923
837 Added 16.94%
5,777 $436,000
Q3 2017

Nov 09, 2017

BUY
$42.37 - $69.67 $209,307 - $344,169
4,940
4,940 $344,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.47B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.